Neuroprotective Agents
Sponsors
Center of Pharmaceutical Chemistry, Center of Molecular Immunology (CIM)
Conditions
Mild to moderate Alzheimer'sParkinson's disease stage II-IIISTROKE
Ischemic strokeSpinocerebellar AtaxiaSpinocerebellar Hereditary Ataxia Type 2mild-moderate Alzheimers disease
Phase 2
Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2
Active, not recruitingRPCEC00000005
Start: 2008-03-30Target: 20Updated: 2026-03-30
NeuroEPO in stroke
Active, not recruitingRPCEC00000282
Start: 2022-04-10Target: 130Updated: 2026-03-30
Phase 3
NeuroEPO in patients with Parkinson disease stage II-III
Active, not recruitingRPCEC00000233
Start: 2017-12-08Target: 102Updated: 2026-03-30
NeuroEPO in patients with Mild-Moderate Alzheimer's disease
Active, not recruitingRPCEC00000232
Start: 2017-12-11Target: 174Updated: 2026-03-30
NeuroEPO-Ataxia-Adults-Phase III
Active, not recruitingRPCEC00000343
Start: 2021-03-01Target: 80Updated: 2026-03-30
NeuroEPO in mild-moderate Alzheimer's disease
RecruitingRPCEC00000409
Start: 2023-03-20Target: 413Updated: 2026-03-30